ULTRAGENYX PHARMACEUTICAL INC. Research and Development Expense
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Research and Development Expense of $167.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for the quarter ending 2026-06-30 was $167.00M, a 1.21% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for the quarter ending 2026-03-31 was $187.00M, a 12.65% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for the quarter ending 2025-12-31 was $203.28M, a 8.18% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for the quarter ending 2025-09-30 was $216.21M, a 27.10% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for fiscal 2025 was $750.00M, a 7.45% increase from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for fiscal 2024 was $698.00M, a 7.72% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for fiscal 2023 was $648.00M, a 8.19% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. research and development expense for fiscal 2022 was $705.79M, a 41.97% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 47 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $167.00M 10-Q · filed 2026-08-05 | $354.00M 10-Q · filed 2026-08-05 | $557.28M derived: sum of 3 quarters · filed 2026-08-05 | $773.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $187.00M 10-Q · filed 2026-05-06 | $390.28M derived: sum of 2 quarters · filed 2026-05-06 | $606.49M derived: sum of 3 quarters · filed 2026-05-06 | $771.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $203.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $419.49M derived: sum of 2 quarters · filed 2026-02-18 | $584.49M derived: sum of 3 quarters · filed 2026-08-05 | $750.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | $216.21M 10-Q · filed 2025-11-05 | $381.21M derived: sum of 2 quarters · filed 2026-08-05 | $546.72M 10-Q · filed 2025-11-05 | $735.11M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $165.00M 10-Q · filed 2026-08-05 | $164.74M 10-Q · filed 2025-08-06 | $331.00M 10-Q · filed 2026-08-05 | $330.51M 10-Q · filed 2025-08-06 | $518.90M derived: sum of 3 quarters · filed 2026-08-05 | $689.01M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $166.00M 10-Q · filed 2026-05-06 | $165.77M 10-Q · filed 2025-05-07 | $353.90M derived: sum of 2 quarters · filed 2026-05-06 | $524.01M derived: sum of 3 quarters · filed 2026-05-06 | $685.51M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $187.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $358.01M derived: sum of 2 quarters · filed 2026-02-18 | $519.51M derived: sum of 3 quarters · filed 2026-02-18 | $698.00M 10-K · filed 2026-02-18 | $697.87M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $170.11M 10-Q · filed 2025-11-05 | $331.61M derived: sum of 2 quarters · filed 2025-11-05 | $510.10M 10-Q · filed 2025-11-05 | $670.21M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-06-30 | $161.50M 10-Q · filed 2025-08-06 | $339.99M 10-Q · filed 2025-08-06 | $500.10M derived: sum of 3 quarters · filed 2026-02-18 | $657.34M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-03-31 | $178.49M 10-Q · filed 2025-05-07 | $338.60M derived: sum of 2 quarters · filed 2026-02-18 | $495.84M derived: sum of 3 quarters · filed 2026-02-18 | $660.79M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | $160.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $317.35M derived: sum of 2 quarters · filed 2026-02-18 | $482.30M derived: sum of 3 quarters · filed 2026-02-18 | $648.00M 10-K · filed 2026-02-18 | $648.45M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $157.25M 10-Q · filed 2024-11-06 | $322.19M derived: sum of 2 quarters · filed 2024-11-06 | $487.89M 10-Q · filed 2024-11-06 | $658.70M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $164.95M 10-Q · filed 2024-08-02 | $330.65M 10-Q · filed 2024-08-02 | $501.45M derived: sum of 3 quarters · filed 2025-02-19 | $738.75M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $165.70M 10-Q · filed 2024-05-03 | $336.51M derived: sum of 2 quarters · filed 2025-02-19 | $573.80M derived: sum of 3 quarters · filed 2025-02-19 | $728.33M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $170.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $408.11M derived: sum of 2 quarters · filed 2025-02-19 | $562.63M derived: sum of 3 quarters · filed 2025-02-19 | $705.79M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $237.30M 10-Q · filed 2023-11-03 | $391.83M derived: sum of 2 quarters · filed 2023-11-03 | $534.98M 10-Q · filed 2023-11-03 | $657.99M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $154.53M 10-Q · filed 2023-08-04 | $297.68M 10-Q · filed 2023-08-04 | $420.70M derived: sum of 3 quarters · filed 2024-02-21 | $534.11M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $143.16M 10-Q · filed 2023-05-05 | $266.17M derived: sum of 2 quarters · filed 2024-02-21 | $379.58M derived: sum of 3 quarters · filed 2024-02-21 | $492.79M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $123.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $236.43M derived: sum of 2 quarters · filed 2024-02-21 | $349.63M derived: sum of 3 quarters · filed 2024-02-21 | $497.15M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $113.42M 10-Q · filed 2022-11-03 | $226.62M derived: sum of 2 quarters · filed 2022-11-03 | $374.14M 10-Q · filed 2022-11-03 | $505.24M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $113.20M 10-Q · filed 2022-07-29 | $260.72M 10-Q · filed 2022-07-29 | $391.82M derived: sum of 3 quarters · filed 2023-02-17 | $479.14M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $147.52M 10-Q · filed 2022-05-06 | $278.62M derived: sum of 2 quarters · filed 2023-02-17 | $365.93M derived: sum of 3 quarters · filed 2023-02-17 | $446.64M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $131.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $218.41M derived: sum of 2 quarters · filed 2023-02-17 | $299.12M derived: sum of 3 quarters · filed 2023-02-17 | $412.08M 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $87.31M 10-Q · filed 2021-11-03 | $168.02M derived: sum of 2 quarters · filed 2021-11-03 | $280.98M 10-Q · filed 2021-11-03 | $364.05M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $80.71M 10-Q · filed 2021-08-03 | $193.67M 10-Q · filed 2021-08-03 | $276.73M derived: sum of 3 quarters · filed 2022-02-15 | $376.88M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | $112.96M 10-Q · filed 2021-05-05 | $196.02M derived: sum of 2 quarters · filed 2022-02-15 | $296.17M derived: sum of 3 quarters · filed 2022-02-15 | $392.21M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $83.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $183.21M derived: sum of 2 quarters · filed 2022-02-15 | $279.25M derived: sum of 3 quarters · filed 2022-02-15 | $357.36M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $100.14M 10-Q · filed 2020-10-27 | $196.19M derived: sum of 2 quarters · filed 2020-10-27 | $274.29M 10-Q · filed 2020-10-27 | $345.91M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | $96.05M 10-Q · filed 2020-07-30 | $174.15M 10-Q · filed 2020-07-30 | $245.77M derived: sum of 3 quarters · filed 2021-02-12 | $315.81M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $78.11M 10-Q · filed 2020-05-07 | $149.72M derived: sum of 2 quarters · filed 2021-02-12 | $219.76M derived: sum of 3 quarters · filed 2021-02-12 | $296.60M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $71.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $141.66M derived: sum of 2 quarters · filed 2021-02-12 | $218.49M derived: sum of 3 quarters · filed 2021-02-12 | $294.00M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | $70.04M 10-Q · filed 2019-11-06 | $146.88M derived: sum of 2 quarters · filed 2019-11-06 | $222.38M 10-Q · filed 2019-11-06 | $283.91M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | $76.83M 10-Q · filed 2019-08-02 | $152.34M 10-Q · filed 2019-08-02 | $213.87M derived: sum of 3 quarters · filed 2020-02-14 | $274.28M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | $75.50M 10-Q · filed 2019-05-07 | $137.03M derived: sum of 2 quarters · filed 2020-02-14 | $197.44M derived: sum of 3 quarters · filed 2020-02-14 | $255.88M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2017-12-31 | $61.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $121.94M derived: sum of 2 quarters · filed 2020-02-14 | $180.38M derived: sum of 3 quarters · filed 2020-02-14 | $231.64M 10-K · filed 2020-02-14 | ||||
| 2017-09-30 | $60.41M 10-Q · filed 2018-11-06 | $118.85M derived: sum of 2 quarters · filed 2018-11-06 | $170.12M 10-Q · filed 2018-11-06 | $220.86M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2017-06-30 | $58.44M 10-Q · filed 2018-08-03 | $109.70M 10-Q · filed 2018-08-03 | $160.45M derived: sum of 3 quarters · filed 2019-02-20 | $209.16M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2017-03-31 | $51.27M 10-Q · filed 2018-05-08 | $102.02M derived: sum of 2 quarters · filed 2019-02-20 | $150.73M derived: sum of 3 quarters · filed 2019-02-20 | $194.06M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2016-12-31 | $50.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $99.46M derived: sum of 2 quarters · filed 2019-02-20 | $142.79M derived: sum of 3 quarters · filed 2019-02-20 | $183.20M 10-K · filed 2019-02-20 | ||||
| 2016-09-30 | $48.71M 10-Q · filed 2017-11-03 | $92.04M derived: sum of 2 quarters · filed 2017-11-03 | $132.46M 10-Q · filed 2017-11-03 | $177.02M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $43.33M 10-Q · filed 2017-07-28 | $83.75M 10-Q · filed 2017-07-28 | $128.31M derived: sum of 3 quarters · filed 2018-02-21 | $158.02M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $40.41M 10-Q · filed 2017-05-05 | $84.98M derived: sum of 2 quarters · filed 2018-02-21 | $114.68M derived: sum of 3 quarters · filed 2018-02-21 | $137.79M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $44.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $74.27M derived: sum of 2 quarters · filed 2018-02-21 | $97.37M derived: sum of 3 quarters · filed 2018-02-21 | $114.74M 10-K · filed 2018-02-21 | ||||
| 2015-09-30 | $29.70M 10-Q · filed 2016-11-08 | $52.81M derived: sum of 2 quarters · filed 2016-11-08 | $70.17M 10-Q · filed 2016-11-08 | $83.69M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $23.10M 10-Q · filed 2016-08-09 | $40.47M 10-Q · filed 2016-08-09 | $53.99M derived: sum of 3 quarters · filed 2017-02-17 | $66.84M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $17.36M 10-Q · filed 2016-05-10 | $30.89M derived: sum of 2 quarters · filed 2017-02-17 | $43.74M derived: sum of 3 quarters · filed 2017-02-17 | $54.98M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $26.38M derived: sum of 2 quarters · filed 2017-02-17 | $37.61M derived: sum of 3 quarters · filed 2017-02-17 | $45.97M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $12.85M 10-Q · filed 2015-11-10 | $24.09M derived: sum of 2 quarters · filed 2015-11-10 | $32.45M 10-Q · filed 2015-11-10 | $40.65M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $11.24M 10-Q · filed 2015-08-14 | $19.59M 10-Q · filed 2015-08-14 | $27.80M derived: sum of 3 quarters · filed 2016-02-26 | $34.56M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $8.35M 10-Q · filed 2015-05-12 | $16.56M derived: sum of 2 quarters · filed 2016-02-26 | $23.32M derived: sum of 3 quarters · filed 2016-02-26 | $30.52M derived: sum of 4 quarters · filed 2016-02-26 | $54.50M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $14.97M derived: sum of 2 quarters · filed 2016-02-26 | $22.16M derived: sum of 3 quarters · filed 2016-02-26 | $27.83M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $6.76M 10-Q · filed 2014-11-10 | $13.96M derived: sum of 2 quarters · filed 2014-11-10 | $19.63M 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | $7.20M 10-Q · filed 2014-08-11 | $12.86M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | $5.66M 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $12.64M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |